Grass pollen allergen-specific immunoglobulin E (sIgE) (sIgE)

Grass pollen allergen-specific immunoglobulin E (IgE) antibodies are the primary drivers of allergic sensitization and clinical symptoms in seasonal allergic rhinitis and asthma [1]. These antibodies are produced by B cells in response to grass pollen proteins, such as those from Timothy grass (Phleum pratense) or Ryegrass (Lolium perenne) [2]. Once produced, sIgE binds to the high-affinity FcεRI receptor on the surface of mast cells and basophils [3]. Upon re-exposure, grass pollen allergens cross-link these IgE molecules, triggering the immediate release of inflammatory mediators like histamine and leukotrienes, which cause sneezing, itching, and airway constriction [4]. Therapeutic interventions include the use of anti-IgE monoclonal antibodies like Omalizumab, which sequester free IgE and prevent its binding to receptors [5]. Additionally, allergen-specific immunotherapy (AIT) targets the production and activity of these antibodies by inducing immune tolerance and the production of protective IgG4 antibodies [6]. Monitoring levels of these specific IgE antibodies is crucial for diagnosing allergies and assessing the efficacy of treatments [7].

Other names

Grass pollen-specific IgEAnti-grass pollen IgEAllergen-specific IgEPhl p-specific IgELol p-specific IgE

Drugs targeting grass pollen-specific IgE primarily work by either neutralizing circulating IgE to prevent its interaction with high-affinity FcεRI receptors on mast cells and basophils, or by modulating the immune system through allergen-specific immunotherapy to reduce IgE synthesis and promote the production of competing IgG4 blocking antibodies [5, 6].